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Purpose/Objectives: Standard 3D-CRT after BCS may cause skin toxicity with a wide range of intensity including
acute effects like erythema or late effects. In order to reduce these side effects it is mandatory to identify potential
factors of influence in breast cancer patients undergoing standard three-dimensional conformal radiation therapy
(3D-CRT) of the breast and modern systemic therapy.
Materials/Methods: Between 2006 and 2010 a total of 211 breast cancer patients (median age 52,4 years, range
24–77) after BCS consecutively treated in our institution with 3D-CRT (50 Gy whole breast photon radiotherapy
followed by 16 Gy electron boost to the tumorbed) were evaluated with special focus on documented skin toxicity
at the end of the 50 Gy-course. Standardized photodocumentation of the treated breast was done in each patient
lying on the linac table with arms elevated. Skin toxicity was documented according to the common toxicity
criteria (CTC)-score. Potential influencing factors were classified in three groups: patient-specific (smoking, age,
breast size, body mass index = BMI, allergies), tumor-specific (tumorsize) and treatment-specific factors
(antihormonal therapy with tamoxifen or aromatase inhibitors, chemotherapy). Uni- and multivariate statistical
analyses were done using IBM SPSS version 19.
Results: After 50 Gy 3D-CRT to the whole breast 28.9% of all 211 patients had no erythema, 62.2% showed
erythema grade 1 (G1) and 8.5% erythema grade 2. None of the patients had grade 3/4 (G3/4) erythema.
In univariate analyses a significant influence or trend on the development of acute skin toxicities (erythema G0
versus G1 versus G2) was observed for larger breast volumes (p=0,004), smoking during radiation therapy (p=0,064)
and absence of allergies (p=0,014) as well as larger tumorsize (p=0,009) and antihormonal therapy (p=0.005).
Neither patient age, BMI nor choice of chemotherapy showed any significant effect on higher grade toxicity. In the
multivariate analysis, factors associated with higher grade skin toxicity were larger breast target volume (p=0,003),
smoking (p=0,034) and absence of allergies (p=0,002).
Conclusion: Patients treated in this study showed less objectively documented skin toxicity after 50 Gy 3D-CRT
compared to similar patient cohorts. Factors associated with higher grade skin toxicity were smoking during 3D-
CRT, absence of allergies and larger breast volumes.
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Table 1 Summary of all relevant patient characteristics:
patient -, tumour- and treatment related parameters
Patient characteristics
(at the beginning of EBRT)
Median Range
Age [years] 52.4 24.3-77.3
Patient weight [kg] 65 44-120
Patient height [cm] 166 150-180
Body-Mass-Index 23.9 17.4-41.8
Breast target volume [cc] 946.9 402-4283
Smoking n %
• no current smoking 146 69.2
• current smoking 41 19.4
• unknown 24 11.4
Allergies
• with allergies 71 33.6
• without allergies 140 66.4
Tumour characteristics n %
Tumour localization
• right-sided 100 47.4
• left-sided 110 52.1
• both sides 1 0.5
Histology
• ductal-invasive 137 64.9
• ductal-invasive + DCIS 29 13.7
• lobular-invasive 15 7.1
• mixed (ductal- and lobular-invasive) 15 7.1
• other 15 7.1
T-stage
• 1 143 67.8
• 2 64 30.3
• 3 3 1.4
• 4 1 0.5
Treatment characteristics 3D-CRT Median Range
Interval BCS – start of 3D-CRT [days] 74 19-393
Interval start of 3D-CRT-boost [days] 38 30-79
Energy levels n %
• 6 MV 168 79.6
• 6 MV/18 MV 39 18.5
• 6 MV/18 MV/23 MV 4 1.9
Systemic therapy
Chemotherapy
• no chemotherapy 104 49.3
• Anthracyclines 59 28.0
• Taxanes 1 0.5
• Anthracyclines and taxanes 45 21.3
• neither anthracyclines nor taxanes 2 1.0
Antihormonal therapy
• no antihormonal therapy 51 24.2
• Tamoxifen 111 52.6
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Adjuvant external beam radiotherapy (EBRT) to the breast
is standard of care after breast-conserving surgery (BCS)
for patients with early-stage breast cancer, in order to
achieve equivalent survival rates compared to those patients
treated with mastectomy [1].
Although potential side effects can be reduced by using
modern treatment techniques and fractionation schedules,
skin erythema, breast edema and breast fibrosis are the
most common side effects after EBRT. Skin toxicity is the
predominant acute side effect of radiotherapy to the breast,
occuring during or after EBRT in more than 90% of all
patients. 10% of these patients develop CTC (common tox-
icity criteria version 2.0) G3 3 erythemas [2,3] that may
limit the patients quality of life and compliance. The sever-
ity of skin reaction varies from mild erythema to moist des-
quamation and occasionally ulceration of the skin.
Radiotherapy treatment related factors such as fractionation
dose, beam energy and treatment technique can influence
the severity of skin toxicity as can patient related factors
such as breast size, breast geometry and smoking: Patients
with larger breast volumes developed more severe skin tox-
icity during radiotherapy compared to patients with smaller
breast volumes and wound-healing of women, who were
smoking during EBRT, was delayed, compared to that of
non-smokers [4]. This present study was designed to assess
influencing factors during EBRT of the breast in a patient
cohort treated in our institution. All patients included in
this study were treated with 3 –dimensional, CT (computer
tomography) - planned conformal radiotherapy (3D-CRT)
and, according to receptor status and individual risk, mod-
ern systemic therapy.
Materials and methods
211 breast cancer patients (median age 52,4 years, range
24–77) with histologically documented diagnosis of breast
cancer were eligible for this study. Patients were treated at
the department of Radiation Oncology, University Medical
Center Mannheim, University of Heidelberg, Germany with
standard 3D-CRT of the breast after breast conserving sur-
gery. A three-dimensional treatment plan (OTP= Oncentra
Treatment PlanW Version 3.3 (Nucletron BV, Veenendaal,
Netherlands) was calculated individually for each patient.
The breast target volume of each patient was measured via
OTP treatment planning system by contouring manually
each slice of breast tissue on planning CT. The treatment
schedule comprised whole breast photon radiotherapy
with energies ranging between 6 and 23 MV (see Table 1)
up to a total dose of 50 Gy followed by 16 Gy electron
boost to the tumorbed. Two Electa (Electa Precise Treat-
ment System™) linear accelerators were used. Daily frac-
tionation was 2.0 Gy. 3D-CRT was performed according
to the International Commission on Radiation Units and
Measurements (ICRU 50) criteria. In order to minimize or
Figure 1 Breast volume and erythema after 50 Gy 3D-CRT
(p= 0,009).
Table 1 Summary of all relevant patient characteristics:
patient -, tumour- and treatment related parameters
(Continued)
• Aromatase inhibitors 49 23.2
Herceptin
• no 191 90.5
• yes 20 9.5
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care during 3D-CRT were given to all patients before
starting radiotherapy: patients should use mild skin
(“baby”) powder once or twice a day during 3D-CRT and
thereafter until skin recovered to normal.and treat them-
selves with local standard of care for the irradiated breast
consisting of deodorant-free After 50 Gy 3D-CRT to the
entire breast a standardized (arms elevated lying at the lin-
ear accelerator table) digital photograph of the irradiated
breast and the intended boost field was done for each pa-
tient and saved in the electronic patient chart system
Mosaiq (Radiation Oncology Information System, Electa
AB, Stockholm, Sweden). All photos were made with the
same camera, the same technique and identical lighting
inside the radiation room.
All data, including medical history including history
of allergies, diagnosis, pathology and treatment reports
were retrospectively evaluated from Mosaiq with special
focus on documented skin toxicity (Common toxicity criteria
CTC version 2.0: grade 0 =0, grade 1 =I, grade 2 =II,
grade 3 =III) at the end of the 50 Gy -course. For that rea-
son all photodocumentions were evaluated independently by
two radiation oncologists blinded for the clinical data.
Uni- and multivariate statistical analyses were done
using IBM SPSS Version 19. For statistical analyses, as
appropriate, chi-square test (or Fisher's exact test), t-test
for independent samples (or Mann–Whitney U-test for inde-
pendent samples), one way ANOVA (or Kruskal Wallis
ANOVA on ranks) and multiple ordinal regression analysis
was used. A significance level of 5% was chosen.
Skin toxicity was scored according to the common tox-
icity criteria (CTC version 2.0)-score. Potential influencing
factors were classified in three groups in order to keep track
on all parameters patient-specific (smoking, age, breast size,
BMI, allergies), tumor-specific (tumorsize) and treatment-
specific factors (antihormonal therapy with tamoxifen or
aromatase inhibitors, chemotherapy).
Table 1 gives a full summary of all relevant patient
characteristics according to patient-, tumour- and treat-
ment characteristics.
Results
211 breast cancer patients treated between 2006 and 2010
at the department of Radiation Oncology, MannheimMedical Centre, University of Heidelberg, Germany for
adjuvant EBRT were enrolled to this study. Median inter-
val between BCS and beginning of EBRT was 74 days
(19–393), median interval between beginning of EBRT
and the 50 Gy time point was 38 days (30–79). After 50
Gy EBRT to the whole breast 28.9% of all patients had no
erythema, 62.6% showed an erythema G 1 and 8.5% an
erythema G 2. None of the patients had III/IV erythema.
In univariate analyses larger tumour size (p=0.009),
antihormonal therapy with aromatase inhibitors (p=0.005),
larger breast volumes (p=0.004), smoking during EBRT
(p=0.064) and absence of allergies (p=0.014) had an influ-
ence on skin toxicity after 3D-CRT (i.e. erythema G0 versus
G1 versus G2).Breast volume
Figure 1: Breast volume and erythema after 50 Gy 3D-
CRT (p= 0,009).Smoking
Figure 2: Smoking and skin toxicity after 50 Gy 3D-CRT
(p= 0,064).Allergies
From all 71 patients with allergies 28 (39%) showed no skin
toxicities at all, 41 (58%) had erythema G1 and 2 (3%)
erythema G2. From patients without allergies 33 (24%)
showed no skin toxicities at all, 91 (65%) had erythema G1
and 16 (11%) erythema G2.
Figure 3: Allergies and skin toxicity after 50
Gy3D-CRT (p=0.014).T-stage
The distribution of patients with no erythema, erythema
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Figure 2 Smoking and skin toxicity after 50 Gy 3D-CRT (p= 0,064).
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Patients with aromatase inhibitors were subclassified
according to their prescribed compound: 24 patients
(11,4%) were treated with Anastrozole (ArimidexW), 24
(11,4%) with Letrozole (FemaraW) and one patient (0,5%)
with Exemestan (AromasinW). Increased acute skin tox-
icity (G 1 erythema) for patients taking Anastrozole
followed by Letrozole was found (p=0,01).
Table 3: Choice of antihormonal therapy and skin tox-
icity after 50 Gy 3D-CRT (p=0.005).
To summarize, patients with aromatase inhibitors (n=49)
developed more often erythema G2 compared to patients
with no antihormonal therapy or with tamoxifen. This dif-
ference was significant (p=0.005).
Figure 5: Antihormonal therapy and skin toxicity after 50
Gy 3D-CRT (p=0.005).
All other parameters such as age, BMI, and chemothe-
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Figure 3 Allergies and skin toxicity after 50 Gy 3D-CRT (p=0.014).Table 4: Age, BMI, Chemotherapy and skin toxicity
after 50 Gy EBRT.
The results of multivariate analysis are summarized in
Table 5. There were significant influences of larger
breast target volume (p=0.003), smoking during EBRT
(p=0.034) and absence of allergies (p=0.002). Nei-
ther patient age, BMI nor adjuvant chemotherapy nor
type of chemotherapy (taxanes versus anthracyclines)
showed a significant effect on higher grade acute skin
toxicity.
Discussion
Progress has been made during the last few years in order
to reduce the side effects of EBRT after breast-conserving
surgery: immobilization devices and modern radiation
techniques like 3D-conformal radiotherapy or intensity-
modulated radiotherapy (IMRT) [5,6]. Although using
modern and highly complex techniques with high energy
photons, going along with decreased skin dose and°|| erythema
BRT
Patients with allergies
Patients with no allergies
Table 2 T-stage and skin toxicity after 50 Gy 3D-CRT
T-stage(n) No erythema n (%) Erythema G 1grade 1 n (%) Erythema G 1grade 1I n (%)
T1/2 ( 207) 61 (29.5) 130 (62.8) 16 (7.7)
T3/4 (4) 0 (0) 2 (50) 2 (50)
All patients (211) 61 (28.9) 132 (62.6) 18 (8.5)
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toxicity during or after radiation therapy [7,8]. Literature
reports erythema rates after standard 3D-CRTat an average
of 90% of the patients, while 10% developed erythema G 3
or 4 10 years ago [2]. However breast cancer treat-
ment includes nowadays other chemotherapies, other
antihormonal therapies and improved radiation therapy
techniques. Patients from our study show lower skin tox-
icity compared to the data from the literature: we found
only 70% erythema G 1 or 2 and no G3 erythema at all.
However the 211 patients from our study were evaluated
after a total dose of 50 Gy, with a single fractionation of 2.0
Gy, while some other authors have collected their data at a
higher dose level or later point of time [7].
The individual reaction of the skin to EBRT with high-en-
ergy photons is complex and depends on numerous factors
that can be patient-, tumour- and/or treatment-related.
Previous studies have tried to identify potential factors
associated with increased radiotherapy –induced toxicity
[8], but many of these studies found no association be-
tween skin toxicity and the above mentioned parameters
at all [9,10]. However the number of included patients was
often too low to find any significant results [11,12]. Fur-
thermore the scoring of the individual skin toxicity is quite
subjective and inaccurate. Observing and evaluating the
photodocumentations at a clearly defined time point in each
of our 211 patients by two independent observers, we tried
to get a more objective rating of individual skin toxicity. We
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Skin toxicity afte
Figure 4 T-stage and skin toxicity after 50 Gy 3D-CRT.patient at a defined time point and scoring according to
CTC-score makes our results objective and useful, while
other studies often collect their results at different time
points using more subjective criteria.
Regarding all parameters of our study with potential in-
fluence on skin toxicity, we found significant correlations in
uni- as well as in multivariate analyses only for the three
patient-related factors breast volume, current smoking and
absence of allergies.
Higher breast volumes
Patients with larger breast volumes developed in our
study significantly more erythema G 1 and 2 compared
to patients with smaller breast volumes.
A study from Vicini and colleagues could show com-
parable results: patients with breast volumes > 1600 cc
had more acute skin toxicity compared to those with
breast volumes < 1000 cc [13]. Another study showed
27% RTOG G 2 erythema and 0% G 3 erythema in
patients with breast volumes < 975 cc, while patients
with breast volumes > 1600 cc developed 59% RTOG G
2 and 3% G 3I erythema (p=0,002) [5]. Breast volumes
were measured in both studies in analogy to our method
(manually contouring of breast target volume).
In another study with a positive correlation between
breast size and skin toxicity published in 2006 larger
breast volumes (here defined as > cup D) were signifi-
cantly associated with higher graded (> G2) skin toxicity
[14], however graduating breast volumes in different cupa °|| erythema
r 50 Gy EBRT
T 1/2
T 3/4
Table 3 Choice of antihormonal therapy and skin toxicity after 50 Gy 3D-CRT (p=0.005)
No erythema Erythema G1 Erythema G2
No antihormonal therapy n 13 35 3
% 25.5 68.6 5.9
Tamoxifen n 28 77 6
% 25.2 69.4 5.4
Anastrozole n 9 9 6
% 37.5 37.5 25
Letrozole n 10 11 3
% 41.7 45.8 12.5
Exemestan n 1 0 0
% 100 .0 .0
Total n 61 132 18
% 28.9 62.6 8.5
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3D volumetry.
Fisher and colleagues summarized their data con-
cerning breast volume and skin toxicity as follows:
patients with small breasts developed ≥ erythema G1 in
11–21%, patients with medium sized breasts in 36-39%
and patients with large breasts in 43-50% [4].
A possible explanation for this correlation might be
that EBRT treatment plans of larger breast volumes have
much more dose inhomogeneities than that of smaller
breasts. These dose inhomogeneities may lead to partial
hot spots followed by increased skin toxicities and can
better be balanced with IMRT techniques [5,15] espe-
cially for patients with larger breast sizes.
Current smoking
All 211 patients were classified in two groups: no
current versus current smoking, Our observation that
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Figure 5 Antihormonal therapy and skin toxicity after 50 Gy 3D-CRTsignificantly more skin toxicity, goes along with a study
from Wells et al. with 357 patients randomized to apply
aqueous cream, sucralfate cream or no cream, who
published increasing skin reactions during EBRT in each
of the three groups in correlation to no smoking, previ-
ous smoking and current smoking patients [16]. Another
group also confirmed smoking as predictive factor for
increased skin toxicity [17] in breast cancer patients.
There are also results from other tumour entities, who
describe a positive correlation between smoking during
radiation therapy and increased skin toxicity evaluating,
for example, patients with anal cancer [18].
Allergies
The development of skin erythemas during radiation
therapy is accompanied by perivascular inflammation
going along amongst others with an accumulation of
mastocytes and cytokines. Due to the fact that patients






Table 4 Age, BMI, Chemotherapy and skin toxicity after
50 Gy EBRT
Median Range
Age All 52.42 24.25-77.29
No erythema 51.87 29.43-77.29
Erythema I 52.25 24.25-73.76
Erythema II 58.05 32.38-68.43
BMI All 23.9 17.4-41.79
No erythema 23.31 17.93-40.56
Erythema I 24.0 17.4-41.79
Erythema II 25.51 17.53-39.79
n %
Chemotherapy No erythema 27 26
Erythema I 67 64.4
Erythema II 10 9.6
No chemotherapy No erythema 34 36.4
Erythema I 65 69.6
Erythema II 8 7.5
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would develop more skin toxicity after EBRT. There are
a few studies dealing with manipulation of this inflam-
matory reaction during EBRT by topical agents with
steroids in order to reduce the skin reactions during ra-
diation therapy. The results of three studies with
restricted numbers of patients showed concordantly that
patients treated with steroid ointments during EBRT
developed significantly less moist skin reactions
[17,19,20]. Porock, in contrast, could not show any benefit
of steroid products used during radiotherapy [21].
In our study patients with the history of allergies
developed in both uni- and multivariate analyses signifi-
cantly less erythemas compared to patients with no al-
lergies. But a clear explanation for this result besides the
statistical significance is still missing.T-stage
Some authors describe a positive correlation between larger
resected tissue volume and higher grade skin toxicityTable 5 Results of the multivariate analysis (ordinal regressio
erythema G 2 at 50 Gy time point
Estimate SE
Breast volume [cc] (continuous) .001 .00
No allergies vs. allergies 1.013 .33
T1/2 vs T2/4 1.482 1.09
AHT aromatase inhibitors vs No AHT .019 .37
AHT aromatase inhibitors vs No AHT -.265 .45
No current Smoking vs current smoking -.819 .38during or after EBRT [7,22], however it is apparently diffi-
cult to exactly differentiate between bad cosmetic outcome
and increased skin toxicity. There are only 4 patients from
our cohort with T3/4-stage disease developing half and half
erythema G1 and 2, therefore it is impossible to draw any
conclusion regarding this point.Anthormonal therapy
A quarter of our patient group received no antihormonal
therapy, about half antihormonal therapy with tamoxifen
and another quarter upfront therapy with aromatase
inhibitors.
There was no significant difference between skin tox-
icity and in patients taking no antihormonal therapy or
taking tamoxifen, but between taking no antihormonal
therapy and taking aromatase inhibitors. Patients with
aromatase inhibitors showed significantly more grade II
erythemas compared to the other two groups.
Numerous studies confirm the finding that there was no
difference between skin toxicity whether taking no
antihormonal medication or taking tamoxifen [23-25]. Our
observation that patients with aromatase inhibitors develop
more skin toxicity after EBRT than patients without
antihormonal therapy or tamoxifen does not coincide with
that described in literature [26,27], where concordantly no
disadvantage with regard to aromatase inhibitors and EBRT
could be found. The subclassification of different aromatase
inhibitors is of restricted value due to small groups.
In contrast to the results of several studies with posi-
tive correlation between body mass index (BMI) and
skin toxicity [6,15,22,23], for our patients BMI had no
positive predictive value, perhaps due to the fact that the
BMI for our total patient cohort was only 23.9 (median)
and for this reason ranging below the threshold of 25
[28,29] with a higher risk of skin toxicity.
Whether chemotherapy before EBRT has a negative
impact on skin toxicity or not, remains unclear. In
addition to our data, there are a few studies that did not
find a significant correlation between chemotherapy and
increased skin toxicity [5,13], on the other hand other
published analyses showed a trend to increased higher
grade skin toxicities after chemotherapy [7,22], at whichn analysis) erythema G 0 versus erythema G 1 versus
Wald df p 95% CI
0 9.031 1 .003 .000; .002
4 9.191 1 .002 .358; 1.669
0 1.851 1 .174 −3.618; .653
6 .003 1 .959 -.718; .757
5 .341 1 .559 −1.156; .625
6 4.498 1 .034 −1.575; .062
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more skin reactions after EBRT [30].
Conclusion
Our retrospective analysis showed less acute skin tox-
icity to comparable patient cohorts treated 10 years ago.
Only the patient specific factors larger breast volumes,
smoking during EBRT and absence of allergies showed
significant influence in multivariate analyses, whereas
larger BMI or receiving chemotherapy before radiother-
apy did not correlate with higher skin toxicity. Larger T-
stages and treatment with aromatase inhibitors showed a
positive trend on the development of higher grade ery-
thema. Consequently patients should be advised not to
smoke. Individualized radiation treatment with IMRT is
justified or even recommended in patients with larger
breast volumes (> 1600 cc).
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